Study: U.K. Cannabis Industry Might Be Worth $2.8B Per Year If These Problems Are Non – Yahoo Finance

0

Benzinga

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. Inside This Week’s EditionWe Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of April 26th — May 2nd, 2021. Without further ado, let’s get started. *Yahoo Finance subscribers, please click here to view the full article. 10. Red White & Bloom Closes Deal With Acreage Holdings to Acquire its Florida Cannabis Operations along with Acquiring Each Of Acreage Holdings’ Florida Operations, RWB Also Acquired Certain Owned and Leased Real Estate Assets Used in Acreage Florida’s Operations Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) announced that the business has closed the purchase of Acreage Florida from Acreage Holdings (CSE: ACRG.A.U) (OTCQX: ACRGF) (FRA: 0VZ). The agreement, which was initially announced via press release on February 25, 2021, sees RWB’s new subsidiary, RWB Florida LLC, officially take control of all of Acreage Florida’s issued and outstanding shares from Acreage Holdings’ subsidiary High Street Capital Partners, LLC. READ FULL RWB ARTICLE 9. COMPASS Pathways Launches Public Offering Cowen, Evercore ISI and Berenberg Are Feeling as Joint Book-Running Managers for the Offering and Cantor Fitzgerald & Co. and BTIG, LLC are Acting as Lead Managers to the Offering Compass Pathways (NASDAQ: CMPS), a mental healthcare company dedicated to accelerating patient accessibility to evidence-based innovation in mental health, announced the launching of a proposed public offering of 4,000,000 American Depositary Shares (ADS), each representing one ordinary share. All the ADSs is currently being offered by COMPASS. COMPASS expects to grant the underwriters a 30-day choice to purchase up to an additional 600,000 ADSs. Green Thumb Industries Reaches Virginia Via Purchase of Dharma Pharmaceuticals Under the Purchase Agreement, Green Thumb Will Also Acquire a Manufacturing Center and Retail Dispensary in Abingdon, Virginia Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) announced Monday it’ll reach the Virginia marketplace via its purchase of Dharma Pharmaceuticals LLC. GTI, the cannabis consumer packaged goods firm, confirmed it had signed a definitive agreement to purchase Dharma Pharmaceuticals, though the cost hasn’t yet been disclosed. Dharma Pharmaceuticals owns one of five permits below the Virginia medical cannabis marketplace, which enables it to nurture, process and retail straight to customers. It was the very first operator to provide medical cannabis products to individuals in Virginia in 2020. READ FULL GTII ARTICLE 7. Revive Therapeutics Enters Into Research Agreement with UCSF As an Bucillamine as Possible Treatment For Severe COVID-19 The Arrangement Will Support Research in the Laboratory of Dr. John Fahy to Test the Efficacy of Bucillamine in Pre-Clinical Versions of COVID-19 and to Design Protocols This Test the Ability of Bucillamine in Human Trials Revive Therapeutics Ltd. (CNSX: RVV, OTCMKTS: RVVTF), a specialization life sciences company focused on the research and development of therapeutics for medical Requirements and uncommon disorders, announced that it has entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to explore the usefulness of Bucillamine for a cure for severe COVID-19. Red White & Bloom Releases Update and Advises on Timing of Filing Annual Audited Financial Statements and Management’s Discussion and Analysis After All Acquisitions Are Closed, RWB and RWB Brands Will be Available at 6 of the Top 10 U.S. States, Measured By Cannabis Revenue, Together with Sales in 2020 Exceeding $8.8 Billion Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) previously announced that it did not document its audit in advance of the April 30, 2021 deadline. The company anticipates filing its 2020 audited financial statements on or before May 31, 2021. As a result of today’s announcement, RWB is supplying particular 2020 and subsequent financial outcomes: READ FULL RED WHITE & BLOOM ARTICLE 5. Creso Pharma Releases Quarterly Activities Report Creso Announced That its Total Q1 2021 Revenue Was A$1,385,000 — up 237 percent From Q4 2020 Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8) announced the launch of its Activities Report for the period ended 31 March 2021, together with its Appendix 4C Quarterly Cash Flow Report. “This quarter indicated Creso’s development to a broader-based pharmaceutical business. Having undertaken a comprehensive search for quality, complementary acquisition opportunities, the provider successfully identified and procured an agreement with psychedelics firm, Halucenex, which, when approved by shareholders, could represent a significant landmark for the organization, as it seems to commercialize new psychedelic-assisted psychotherapy remedies. Halucenex has made appreciable progress throughout the quarter and supplies Creso with access to some other thriving vertical,” explained Adam Blumenthal, Creso Pharma Non-Executive Chairman. READ FULL CPH ARTICLE 4. Psychedelics Company MindMed Trips in Nasdaq Debut Psychedelic Drug Development Startup MindMed Became the Second Company of its Kind to List to the NASDAQ on Tuesday, But its Share Cost Crashed 30% During the First Day of Trading MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: MMQ) which went public on Canada’s NEO stock exchange via a reverse takeover in March 2020 and includes a current market cap of $1.3 billion, and is currently working on clinical trials to explore the medicinal properties of strong psychedelics, including lysergic acid diethylamide, MDMA, psilocybin. Cantor Raises Price Target on Trulieve’s Stock Ahead of Q1 Earnings Report Cannabis Company Trulieve is Scheduled to unleash its Q1 2021 Financial Results on May 13, Ahead of the Market , and Will Follow Up Using a Conference Phone at 8.30 AM EST Ahead of their earnings report, Cantor Fitzgerald’s Pablo Zuanic raised the price target to $89 from $83 on Trulieve’s (CSE: TRUL) (OTCQX: TCNNF) stock, while keeping an”Overweight” rating. Zuanic stated Cantor Fitzgerald raised the price target according to improved long-term EBITDA projections. READ FULL TRUL ARTICLE 2. Champignon Brands Changes Name to Braxia Scientific to Reduce the Integration of Ketamine and Psychedelic Schemes as well as its Research and Development Priorities The Name Change Reflects the Company’s Commitment to Providing accessibility to, and Leadership in, Setting the Standard of Care for Ketamine Treatment in Depression During its Network of Clinics, as Well as its Ketamine and Psychedelic Derivative Research and Drug Development Priorities Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced that it has changed its title by”Champignon Brands Inc.” to”Braxia Scientific Corp.” and its ticker symbol will change from”SHRM” to”BRAX” to the Canadian Securities Exchange (CSE). Braxia Scientific’s overarching goal is to shape the future of treatment for people suffering from depression and other mental health disorders. Tilray, Aphria Close Merger, Create The’New’ Tilray In April, Aphria Shareholders Finally Voted in Favor of the Merger, With Tilray Shareholders After Suit Approving the paychecks Friday Tilray (NASDAQ: TLRY) (FRA: 2HQ) along with Aphria (NYSE: APHA) have united after months of negotiations, creating a company with an established market cap of $3.3 billion. The two Canadian cannabis giants were in discussions since December with Aphria’s current CEO Irwin Simon to create a new business. The resulting firm, which can be expected to generate approximately $81 million in annual pre-tax cost synergies over the following ten months, kept the Tilray title also will continue to trade on Nasdaq Global Select Exchange under the ticker symbol TLRY. READ FULL APHA TLRY ARTICLE Picture Sourced from Pixabay Watch more from BenzingaClick below for options trades from BenzingaCannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The WeekCannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week© 2021 Benzinga.com. Benzinga doesn’t offer investment advice. All rights reserved.

Benzinga

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. Inside This Week’s EditionWe Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of April 26th — May 2nd, 2021. Without further ado, let’s get started. *Yahoo Finance subscribers, please click here to view the full article. 10. Red White & Bloom Closes Deal With Acreage Holdings to Acquire its Florida Cannabis Operations along with Acquiring Each Of Acreage Holdings’ Florida Operations, RWB Also Acquired Certain Owned and Leased Real Estate Assets Used in Acreage Florida’s Operations Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) announced that the firm has closed the purchase of Acreage Florida from Acreage Holdings (CSE: ACRG.A.U) (OTCQX: ACRGF) (FRA: 0VZ). The agreement, which was initially announced via press release on February 25, 2021, sees RWB’s new subsidiary, RWB Florida LLC, officially take control of all of Acreage Florida’s issued and outstanding shares from Acreage Holdings’ subsidiary High Street Capital Partners, LLC. READ FULL RWB ARTICLE 9. COMPASS Pathways Launches Public Offering Cowen, Evercore ISI and Berenberg Are Feeling as Joint Book-Running Managers for the Offering and Cantor Fitzgerald & Co. and BTIG, LLC are Acting as Lead Managers to the Offering Compass Pathways (NASDAQ: CMPS), a mental healthcare company dedicated to accelerating patient accessibility to evidence-based innovation in mental health, announced the launching of a proposed public offering of 4,000,000 American Depositary Shares (ADS), each representing one ordinary share. All the ADSs is currently being offered by COMPASS. COMPASS expects to grant the underwriters a 30-day choice to purchase up to an additional 600,000 ADSs. Green Thumb Industries Reaches Virginia Via Purchase of Dharma Pharmaceuticals Under the Purchase Agreement, Green Thumb Will Also Acquire a Manufacturing Center and Retail Dispensary in Abingdon, Virginia Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) announced Monday it’ll reach the Virginia marketplace via its purchase of Dharma Pharmaceuticals LLC. GTI, the cannabis consumer packaged goods firm, confirmed it had signed a definitive agreement to purchase Dharma Pharmaceuticals, though the cost hasn’t yet been disclosed. Dharma Pharmaceuticals owns one of five permits below the Virginia medical cannabis marketplace, which enables it to nurture, process and retail straight to customers. It was the very first operator to provide medical cannabis products to individuals in Virginia in 2020. READ FULL GTII ARTICLE 7. Revive Therapeutics Enters Into Research Agreement with UCSF As an Bucillamine as Possible Treatment For Severe COVID-19 The Arrangement Will Support Research in the Laboratory of Dr. John Fahy to Test the Efficacy of Bucillamine in Pre-Clinical Versions of COVID-19 and to Design Protocols This Test the Ability of Bucillamine in Human Trials Revive Therapeutics Ltd. (CNSX: RVV, OTCMKTS: RVVTF), a specialization life sciences company focused on the research and development of therapeutics for medical Requirements and uncommon disorders, announced that it has entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to explore the usefulness of Bucillamine for a remedy for severe COVID-19. Red White & Bloom Releases Update and Advises on Timing of Filing Annual Audited Financial Statements and Management’s Discussion and Analysis After All Acquisitions Are Closed, RWB and RWB Brands Will Be Available in 6 of the Top 10 U.S. States, Measured By Cannabis Revenue, Together with Sales in 2020 Exceeding $8.8 Billion Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) previously announced that it did not document its audit in advance of the April 30, 2021 deadline. The company anticipates filing its 2020 audited financial statements on or before May 31, 2021. As a result of today’s announcement, RWB is supplying particular 2020 and subsequent financial outcomes: READ FULL RED WHITE & BLOOM ARTICLE 5. Creso Pharma Releases Quarterly Activities Report Creso Announced That its Total Q1 2021 Revenue Was A$1,385,000 — up 237 percent From Q4 2020 Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8) announced the launch of its Activities Report for the period ended 31 March 2021, together with its Appendix 4C Quarterly Cash Flow Report. “This quarter indicated Creso’s development to a broader-based pharmaceutical business. Having undertaken a comprehensive search for quality, complementary acquisition opportunities, the provider successfully identified and procured an agreement with psychedelics firm, Halucenex, which, when approved by shareholders, could represent a significant landmark for the organization, as it seems to commercialize new psychedelic-assisted psychotherapy remedies. Halucenex has made appreciable progress throughout the quarter and supplies Creso with access to some other thriving vertical,” explained Adam Blumenthal, Creso Pharma Non-Executive Chairman. READ FULL CPH ARTICLE 4. Psychedelics Company MindMed Trips in Nasdaq Debut Psychedelic Drug Development Startup MindMed Became the Second Company of its Kind to List to the NASDAQ on Tuesday, But its Share Cost Crashed 30% During the First Day of Trading MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: MMQ) which went public on Canada’s NEO stock exchange via a reverse takeover in March 2020 and includes a current market cap of $1.3 billion, and is currently working on clinical trials to explore the medicinal properties of strong psychedelics, including lysergic acid diethylamide, MDMA, psilocybin. READ FULL MMED ARTICLE 3. Cantor Raises Price Target on Trulieve’s Stock Ahead of Q1 Earnings Report Cannabis Company Trulieve is Scheduled to unleash its Q1 2021 Financial Results on May 13, Ahead of the Market , and Will Follow Up Using a Conference Phone at 8.30 AM EST Ahead of their earnings report, Cantor Fitzgerald’s Pablo Zuanic raised the price target to $89 from $83 on Trulieve’s (CSE: TRUL) (OTCQX: TCNNF) stock, while keeping an”Overweight” rating. Zuanic stated Cantor Fitzgerald raised the price target according to improved long-term EBITDA projections. READ FULL TRUL ARTICLE 2. Champignon Brands Changes Name to Braxia Scientific to Reduce the Integration of Ketamine and Psychedelic Schemes as well as its Research and Development Priorities The Name Change Reflects the Company’s Commitment to Providing accessibility to, and Leadership in, Setting the Standard of Care for Ketamine Treatment in Depression During its Network of Clinics, as Well as its Ketamine and Psychedelic Derivative Research and Drug Development Priorities Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced that it has changed its title by”Champignon Brands Inc.” to”Braxia Scientific Corp.” and its ticker symbol will change from”SHRM” to”BRAX” to the Canadian Securities Exchange (CSE). Braxia Scientific’s overarching goal is to shape the future of treatment for people suffering from depression and other mental health disorders. READ FULL SHRM ARTICLE 1. Tilray, Aphria Close Merger, Create The’New’ Tilray In April, Aphria Shareholders Finally Voted in Favor of the Merger, With Tilray Shareholders After Suit Approving the paychecks Friday Tilray (NASDAQ: TLRY) (FRA: 2HQ) along with Aphria (NYSE: APHA) have united after months of negotiations, creating a company with an established market cap of $3.3 billion. The two Canadian cannabis giants were in discussions since December with Aphria’s current CEO Irwin Simon to create a new business. The resulting firm, which is expected to generate approximately $81 million in annual pre-tax cost synergies over the following ten months, kept the Tilray title also will continue to trade on Nasdaq Global Select Exchange under the ticker symbol TLRY. READ FULL APHA TLRY ARTICLE Picture Sourced from Pixabay Watch more from BenzingaClick below for options trades from BenzingaCannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The WeekCannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week© 2021 Benzinga.com. Benzinga doesn’t offer investment advice. All rights reserved.

Source: https://finance.yahoo.com/news/study-u-k-cannabis-industry-190938963.html

Leave a Reply